BD company Wikipedia

Food and Drug Administration and worldwide health agencies to coordinate recall activities. The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America. BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products. They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations. Embecta Corporation is a standalone public company focused on diabetes care.

BD Specimen Management

Designed and validated for use with cell suspensions, whole blood and tissue pieces. BD Horizon RealViolet™ 544 Reagents offer limited spillover, robust intracellular performance and lot-to-lot consistency. In December 2025, BD was sued by Tela Bio Inc., makers of a ovine forestomach matrix hernia mesh, who alleged that BD engaged in anticompetitive practices to push Tela out of the market for surgical meshes while raising prices for providers and patients.

BD Interventional

The company’s line of plastic conical screwtop test tubes, known as ‘Falcon tubes’, is popular and the term is sometimes used as a generic term for such tubes. In certain places, BD Medical also offers consulting and analytics related services. In 2024, BD announced it would acquire Edwards Lifesciences’ critical care unit for $4.2 billion.

This agreement protects patents and intellectual properties of both companies ensuring the quality and integrity of Embecta Corporation’s cannulas used in their products. The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard. In October 2014, the company agreed to acquire CareFusion for a price of US$12.2 billion in cash and stock. Later Retractable would claim BD was falsely advertising its own brand of retractable needle as the “world’s sharpest needle”. Retractable would accuse BD of patent infringement after BD released a retractable needle of its own. The lawsuit touched off a series of legal conflicts between the companies.

• BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products.
• Bard, Inc. and its parent company BD were fined $60 million USD for failing to adequately inform patients about health risks related to their transvaginal mesh devices.
• A comprehensive suite of trusted products, integrated solutions, useful tools and a wealth of information to advance your flow cytometry applications.
• The name “embecta” represents the company’s commitment to people living with diabetes and its corporate heritage, with the “em-” prefix evoking empathy for people living with diabetes and the empowerment of the new company and the “bect” imbibed from Becton.
• Fill out the form to receive updates on our latest products and innovations, exclusive promotions, educational tours, and other exciting news.

Our Purpose drives us to create innovative solutions that make a meaningful impact on advancing the world of health™. Surgical efficiency, patient safety and outcomes, procedural cost management Use a variety of training courses for instruments and applications to take full advantage of the capabilities of BD products. Explore our webinar series spanning a broad range of topics and in-depth reviews by senior scientists, professionals and clinicians. Houses many of our pre-designed multicolor flow cytometry panels. Explore a variety of tools for your multicolor flow cytometry, from panel design to selection tools—an array of aids to support your research.

Bard, Inc. and its parent company BD were fined $60 million USD for failing to adequately inform patients about health risks related to their transvaginal mesh devices. BD Medical’s Consulting services are primarily targeted at hospitals, healthcare systems and networks of healthcare providers.citation needed A comprehensive suite of trusted products, integrated solutions, useful tools and a wealth of information to advance your flow cytometry applications. The name “embecta” represents the company’s commitment to people living with diabetes and its corporate heritage, with the “em-” prefix evoking empathy for people living with diabetes and the empowerment of the new company and the “bect” imbibed from Becton. Becton, Dickinson and Company (BD; also Becton Dickinson or Becton) is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents.

In March 2021 BD announced a recall of infusion sets for CC, GP, VP, GW/GW800, SE, and IVAC 590 Alaris Pumps and gravity infusion sets and connectors following the news that a supplier falsified sterilisation documents going back ten years. BD announced that it notified customers about the recall by letter and has been working with the U.S. The recall was initiated strategy crazy time on Oct. 28, 2009 after BD received complaints of problems due to air entry through a part of the device. BD stated that the use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. In February 2010 BD announced a voluntary product recall of certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems. In April 2016, the Occupational Safety and Health Administration fined BD US$112,700 for safety violations.